NCT06053658View on ClinicalTrials.gov

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2028

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Tivozanib

Given by PO

DRUG

Nivolumab

Given by IV (vein)

Trial Locations (5)

48109

RECRUITING

University of Michigan, Ann Arbor

75390

RECRUITING

UT Southwestern Medical Center, Dallas

77030

RECRUITING

M D Anderson Cancer Center, Houston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

AVEO Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER